GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc ('Company').
On 30 June 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £13.45 per Ordinary Share, and notional ADSs at a price of $42.20 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2015 to 30 June 2015:
Non Executive Director |
Ordinary Shares |
No. of ADSs |
Sir Philip Hampton |
2,730.912 |
|
Professor Sir Roy Anderson |
673.792 |
|
Dr Stephanie Burns |
|
539.199 |
Stacey Cartwright |
534.387 |
|
Lynn Elsenhans |
|
1,070.720 |
Judy Lewent |
|
457.147 |
Sir Deryck Maughan |
|
1,359.719 |
Dr Daniel Podolsky |
|
1,019.789 |
Urs Rohner |
589.536 |
|
Hans Wijers |
534.387 |
|
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 1 July 2015.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
1 July 2015